Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

Market report details market prospects for SNP analysis

Kalorama Information : 26 June, 2008  (Company News)
A new report from Kalorama Information has concluded that the recent passage of the Genetic Information Nondisclosure Act (GINA) should alleviate privacy concerns surrounding the use of genetic testing, and open up the market for technologies such as SNP analysis.
The report entitled SNP Genotyping Markets and Analysis’ studies the market for SNPs (single nucleotide polymorhpisms), which are variations at a single site in DNA, which have become appealing for several reasons they are numerous, stable, easy to score and account for 80 to 90 percent of genetic variation, which makes them ideal for the task of hunting for correlations between genotype and phenotype. That means SNP analysis could indicate the likelihood of a disease in a patient or the effectiveness of a drug therapy and thus could have useful applications in pharmacogenomics, pharmacogenetics, and clinical testing.

Mainly carried out in core labs, SNP analysis has been adopted in most of the same places as sequencing and PCR, with a slightly different focus, probably due to the higher costs typically involved, as well as the different advantages. The emphasis of most research has been on finding near-term uses for SNPs in diagnostics, biotechnology and drug development as opposed to pursuing basic research questions.

“The most significant barrier to the future of SNPs, or any genetic analysis, is the concern for privacy,” said Bruce Carlson, publisher of Kalorama Information “Costs of technology will tend to go down over time, but if patients are afraid to get tested because they think it will affect them down the line, that would stunt growth. GINA, once signed into law, could go a long way towards reducing concerns.”

Kalorama expects demand for SNP analysis to be strong, due to the many applications with proven value in the life sciences. Revenues of $625 million in 2007 are expected to grow by a solid double-digit annual growth rate to over $2.2 billion by 2013. The bulk of this revenue will be consumables, with software and instruments making up the remainder.

Kalorama Information’s report SNP Genotyping Markets and Analysis’ details the latest trends, developments, challenges, and applications in this rapidly expanding area of genetics.
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 ProHealthServiceZone.com
Netgains Logo